Lung Cancer | Specialty

Veliparib Falls Short in Phase III NSCLC, TNBC Trials

April 21st 2017

Veliparib failed to meet the primary endpoint in phase III non-small cell lung cancer and triple-negative breast cancer trials.

Dr. Chaft on Ongoing Pivotal Trials in EGFR-Mutant NSCLC

April 19th 2017

Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses pivotal ongoing clinical trials in the landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Gandhi on Sequencing and Emerging Agents in ALK+ NSCLC

April 19th 2017

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses sequencing challenges as well as emerging agents in the field of ALK-positive non–small cell lung cancer (NSCLC).

Dr. Costa on Biomarkers Beyond PD-L1 for Immunotherapy in NSCLC

April 19th 2017

Daniel B. Costa, MD, PhD, MMSc, associate professor of medicine at Harvard Medical School, medical staff, Hematology/Oncology, medical director of the Cancer Clinical Trials Office, and Medical Center Thoracic Oncology Group Leader, of Beth Israel Deaconess Medical Center, discusses biomarkers beyond PD-L1 in development for immunotherapy in patients with non–small cell lung cancer (NSCLC).

Brahmer Highlights 5-Year Nivolumab Findings in NSCLC

April 18th 2017

Julie R. Brahmer, MD, discusses the 5-year findings of nivolumab in non-small cell lung cancer, their significance, and expected next steps for this research.

Immunotherapy Agents, Combinations to Compete for Frontline NSCLC

April 17th 2017

Sukhmani Padda, MD discusses the status of ongoing clinical trials participating in this race to the frontline setting in lung cancer.

Dr. Heymach on Nivolumab for Lung Cancer

April 14th 2017

John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses efficacy findings with nivolumab (Opdivo) results for patients with metastatic lung cancer.

Liquid Biopsy Testing Detects Recurrence in High-Risk NSCLC

April 13th 2017

The results of a recent prospective study demonstrate that circulating tumor cells can reveal disease recurrence an average of 6 months prior to conventional imaging in patients with locally advanced non–small cell lung cancer, findings that may help support the use of liquid biopsies to monitor high-risk patients in conjunction with screening.

Alectinib Beats Crizotinib in Frontline ALK+ NSCLC ALEX Trial

April 10th 2017

Alectinib reduced the risk of disease progression or death compared with crizotinib as a frontline treatment for patients with ALK-positive non–small cell lung cancer, according to findings from the phase III ALEX trial.

Dr. Costin on Frontline Immunotherapy for Patients With NSCLC

April 8th 2017

Daniel Costin, MD, hematology and oncology, White Plains Hospital, discusses the potential with immunotherapy agents in the frontline setting as treatment for patients with non–small cell lung cancer (NSCLC).

Dr. Heymach Discusses the CheckMate-026 Study in Lung Cancer

April 7th 2017

John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the CheckMate-026 trial in lung cancer.

Future of Immunotherapy Use in Lung Cancer

April 6th 2017

Atezolizumab Versus Other Immunotherapy Options

April 6th 2017

FDA Approval of Atezolizumab for NSCLC

April 6th 2017

Immunotherapy in Chemorefractory Lung Cancer

April 6th 2017

Historic Perspective on Immunotherapy in Lung Cancer

April 6th 2017

Frontline Setting for ALK+ NSCLC Set to Undergo Shift

April 5th 2017

Leena Gandhi, MD, PhD, discusses emerging developments in the first-line treatment for patients with ALK-positive NSCLC, as well as novel agents emerging in the field.

Dr. Brahmer on 5-Year Follow-Up Data for Nivolumab in NSCLC

April 4th 2017

Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses 5-year follow-up data from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC).

Alectinib Improves PFS in Phase III ALK+ NSCLC Trial

April 4th 2017

In findings from the phase III ALUR trial, alectinib significantly improved progression-free survival compared with chemotherapy in patients with ALK-positive non-small cell lung cancer who had progressed following treatment with platinum-based chemotherapy and crizotinib (Xalkori).

Dr. Arenberg on Low-Cost Intervention to Improve Tobacco Cessation for Lung Cancer

April 3rd 2017

David Arenberg, MD, associate professor, Department of Internal Medicine at the University of Michigan, discusses preliminary results of a low-cost intervention to improve tobacco cessation practices within a large university health system.